Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Company Deals

Cellular Intelligence Acquires Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy Program, Plans AI-Driven Acceleration

Fineline Cube May 13, 2026
Company Deals

Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal

Fineline Cube May 13, 2026
Policy / Regulatory

Hong Kong to Launch FDA-Style Medical Products Regulation Center by Year-End, Creating Gateway for Chinese Innovative Drugs

Fineline Cube May 13, 2026
Company Drug

Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials

Fineline Cube May 13, 2026
Company Drug

Servier’s B7-H4 ADC Emiltatug Ledadotin Receives FDA Breakthrough Therapy Designation for Advanced Adenoid Cystic Carcinoma

Fineline Cube May 13, 2026
Company Deals

LTZ Therapeutics Secures $40M Series A+ to Advance Immunotherapy Pipeline

Fineline Cube Apr 27, 2025

Shenzhen-based LTZ Therapeutics has reportedly raised USD 40 million in a Series A+ financing round...

Company

Amgen Announces $900M Investment to Expand Ohio Manufacturing

Fineline Cube Apr 27, 2025

US biotech leader Amgen (NASDAQ: AMGN) announced a USD 900 million investment to expand its...

Company Drug

Johnson & Johnson’s Tremfya Approved by EC for Ulcerative Colitis Treatment

Fineline Cube Apr 27, 2025

US giant Johnson & Johnson (J&J; NYSE: JNJ) announced that it has received regulatory approval...

Company Drug

Keymed Biosciences Gains NMPA Approval for Phase I/II Study of CM518D1

Fineline Cube Apr 27, 2025

China-based Keymed Biosciences Inc. (HKG: 2162) announced that it has received approval from the National...

Company Drug

Akeso’s Ivonescimab Approved by NMPA for First-Line PD-L1-Positive NSCLC

Fineline Cube Apr 27, 2025

China-based Akeso, Inc. (HKG: 9926) announced that its supplementary New Drug Application (sNDA) for ivonescimab,...

Company Drug

Hefei Lifeon Gains NMPA Approval for Nexletol Clinical Trials in China

Fineline Cube Apr 26, 2025

China-based Hefei Lifeon Pharmaceutical Co., Ltd (SHE: 003020) announced that it has received clinical trial...

Company Drug

Fujian Cosunter Gains NMPA Clearance for Phase II HBV Study of GST-HG131 and GST-HG141

Fineline Cube Apr 26, 2025

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) announced that it has received clearance from...

Company Drug

Anhui Anke’s Allogeneic CAR-T Therapy UTAA09 Approved for r/r B-ALL Trials

Fineline Cube Apr 25, 2025

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that its joint venture with...

Company Drug

Juventas Cell Therapy’s CNCT 19 Gains NMPA Approval for Refractory Lupus Nephritis

Fineline Cube Apr 25, 2025

China-based Juventas Cell Therapy Ltd announced that its chimeric antigen receptor (CAR)-T cell therapy, inaticabtagene...

Company Drug

TYK Medicines Submits Pre-NDA Package for Asandeutertinib in NSCLC Brain Metastasis

Fineline Cube Apr 25, 2025

China-based TYK Medicines, Inc. (HKG: 2410) announced the formal submission of a pre-NDA communication package...

Company Medical Device

MicroPort Scientific’s MRI-Conditional ALIZEA Hybrid Pacing System Secures CE Certification

Fineline Cube Apr 25, 2025

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853), through its French subsidiary MicroPort Cardiac...

Company Drug

AbbVie Files BLA for TrenibotE in Moderate to Severe Glabellar Lines Treatment

Fineline Cube Apr 25, 2025

US-based AbbVie (NYSE: ABBV) announced that it has filed a Biologics License Application (BLA) with...

Company Drug

GenFleet’s KRAS G12D Inhibitor GFH375/VS-7375 Gains FDA Trial Approval

Fineline Cube Apr 25, 2025

Shanghai-based biotech GenFleet Therapeutics announced that its GFH375/VS-7375, an oral KRAS G12D inhibitor co-developed with...

Company Deals Drug

Innate Pharma and Sanofi Restructure 2016 Research Agreement on CD123 ANKET Drug

Fineline Cube Apr 25, 2025

France-based Innate Pharma SA has announced a significant adjustment to its 2016 research and licensing...

Company Medical Device

Medtronic Submits 510(k) Applications for Interoperable Diabetes Management System

Fineline Cube Apr 25, 2025

US-Irish firm Medtronic plc (NYSE: MDT) has submitted twin 510(k) applications to the U.S. Food...

Company Medical Device

Thermo Fisher Announces $2 Billion US Investment to Strengthen Life Sciences Infrastructure

Fineline Cube Apr 25, 2025

US-based life sciences giant Thermo Fisher Scientific Inc. (NYSE: TMO) has announced a USD 2...

Company Deals

Merck KGaA Nears Completion of $3.5 Billion Acquisition of SpringWorks Therapeutics

Fineline Cube Apr 25, 2025

German pharmaceutical major Merck KGaA (ETR: MRK) is reportedly nearing the completion of its acquisition of...

Company Deals

CN Bio and Pharmaron Partner to Validate and Expand OOC Technology Applications

Fineline Cube Apr 25, 2025

CN Bio, a UK-based provider of Organ-on-a-chip (OOC) systems and solutions, has entered into a...

Company

Gan & Lee Pharmaceuticals Reports 417 Million USD Revenue and 80.75% Profit Surge in 2024

Fineline Cube Apr 25, 2025

Gan & Lee Pharmaceuticals (SHA: 603087) reported revenues of RMB 3.045 billion (USD 417 million)...

Company Drug

Hepalink Secures SAHPRA Approval for Ivenoxin in South Africa

Fineline Cube Apr 25, 2025

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE: 002399, HKG: 9989) has announced that it has...

Posts pagination

1 … 170 171 172 … 665

Recent updates

  • Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform
  • Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials
  • Legend Biotech Reports 56% Q1 Revenue Growth to $305M, Driven by Carvykti Sales Surge and J&J Milestone Payment
  • Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms
  • Sichuan Kelun-Biotech Receives NMPA Approval for ITGB6-Targeted ADC SKB105 in Advanced Solid Tumors Following Crescent Biopharma Licensing Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Company Drug

Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials

Company

Legend Biotech Reports 56% Q1 Revenue Growth to $305M, Driven by Carvykti Sales Surge and J&J Milestone Payment

Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.